Eur Rev Med Pharmacol Sci 2019; 23 (15): 6548-6553

DOI: 10.26355/eurrev_201908_18540

Hsa-miR-337 inhibits non-small cell lung cancer cell invasion and migration by targeting TCF7

J. Zhang, W.-H. Gong, Y. Li, H.-Y. Zhang, C.-X. Zhang

Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, China. dashun1210@163.com


OBJECTIVE: Recent studies have revealed that microRNAs (miRNAs) play a crucial role in the progression of tumorigenesis. Non-small cell lung cancer (NSCLC) is one of the most common malignancies worldwide. The aim of this study was to identify the exact role of hsa-miR-337 in the progression of NSCLC and to investigate the possible underlying mechanism.
PATIENTS AND METHODS: Hsa-miR-337 expression in NSCLC cells and 60 paired tissue samples were detected by Real Time-quantitative Polymerase Chain Reaction (RT-qPCR). Moreover, the functions of hsa-miR-337 in vitro were identified by transwell assay and wound healing assay, respectively. Furthermore, the underlying mechanism was explored by RT-qPCR, Western blot assay, and luciferase assay.
RESULTS: The expression level of hsa-miR-337 in NSCLC tissues was remarkably down-regulated when compared with that of adjacent normal samples. Moreover, the invasion and migration of NSCLC cells were significantly inhibited after overexpression of hsa-miR-337 in vitro. Moreover, after overexpression of hsa-miR-337 in vitro, the mRNA and protein levels of TCF7 were significantly down-regulated. Besides, the expression of TCF7 in NSCLC tissues was negatively correlated with the expression of hsa-miR-337.
CONCLUSIONS: The above results suggested that hsa-miR-337 could repress the migration and invasion of NSCLC cells through directly targeting TCF7. Furthermore, hsa-miR-337 might offer a new therapeutic intervention for NSCLC patients.

Free PDF Download

To cite this article

J. Zhang, W.-H. Gong, Y. Li, H.-Y. Zhang, C.-X. Zhang
Hsa-miR-337 inhibits non-small cell lung cancer cell invasion and migration by targeting TCF7

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 15
Pages: 6548-6553
DOI: 10.26355/eurrev_201908_18540